Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Elrexfio (elranatamab-bcmm) is a bispecific antibody that connects a T-cell (via CD3) to myeloma cells (via BCMA), directing the immune system to attack cancer cells. It is indicated for the treatment of adults with:
It is a prescription oncology medicine administered in a hospital or specialized clinical setting, under the supervision of a qualified hematologist-oncologist familiar with cytokine release syndrome management.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Boxed Warning — Cytokine Release Syndrome (CRS) and Neurologic Toxicity: Elrexfio can cause life-threatening or fatal CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). Because of these risks, Elrexfio is only available through a restricted program (the ELREXFIO REMS), requiring prescriber, pharmacy, and healthcare facility certification.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient's treating hospital, coordinated with their inpatient monitoring plan given the initial hospitalization requirement.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Elrexfio (elranatamab-bcmm) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Elrexfio (elranatamab-bcmm injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Elrexfio is not commercially marketed in India.
However, patients in India can legally access Elrexfio through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription. Given the hospitalization requirement for its step-up doses, Elrexfio must be administered at a hospital equipped to monitor and manage cytokine release syndrome.
Elrexfio received accelerated US FDA approval in 2023, ensuring full transparency throughout the process.
Elrexfio can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) can source Elrexfio from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Elrexfio requires cold-chain handling throughout transit and must be kept refrigerated between 2°C to 8°C until use. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, coordinated with the treating hospital's inpatient monitoring schedule for the initial doses.
For Elrexfio cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Elrexfio through regulated import pathways, with delivery coordinated with the treating hospital's inpatient monitoring plan, based on a valid hematologist's prescription.
A major hematology hub with institutions like Tata Memorial, Mumbai coordinates access to advanced myeloma therapies like Elrexfio for eligible patients.
As part of the Delhi NCR region, the city has a strong concentration of hematology specialists, making it a key location for accessing bispecific antibody treatments.
With a growing network of multispecialty hospitals, Bangalore supports access to Elrexfio through structured import pathways guided by treating specialists.
Home to several reputed hematology centers, Chennai facilitates access to Elrexfio for patients with heavily pretreated multiple myeloma.
A growing hub for specialty care, Hyderabad supports coordinated access to Elrexfio for eligible patients under specialist supervision.
Eastern India's leading medical centers in Kolkata coordinate Elrexfio access for patients with advanced myeloma.
With an expanding base of hematology clinics, Pune facilitates timely access to Elrexfio under prescription.
Gujarat's leading hospitals support regulated access to Elrexfio for eligible patients.
Kerala's healthcare network, including major hospitals in Kochi, coordinates access to advanced bispecific antibody therapies like Elrexfio.
Serving North India, Chandigarh's specialist centers facilitate access to Elrexfio for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Elrexfio through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Elrexfio under specialist care.
Odisha's growing specialty healthcare sector supports patient access to Elrexfio.
As a referral hub for the North-East, Guwahati facilitates access to Elrexfio for patients across the region.
Access can also be coordinated for patients in other major Indian cities with hospitals equipped for CRS monitoring, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
